Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 4
1997 5
1998 4
1999 3
2000 2
2001 2
2002 1
2003 2
2004 1
2005 1
2012 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Transdermal alniditan delivery by skin electroporation.
Jadoul A, Lecouturier N, Mesens J, Caers W, Préat V. Jadoul A, et al. J Control Release. 1998 Aug 14;54(3):265-72. doi: 10.1016/s0168-3659(97)00195-8. J Control Release. 1998. PMID: 9766246
The aim of this study was to evaluate the transdermal permeation of alniditan by electroporation and to compare with iontophoretic delivery. ...Both transport during and after pulsing were shown to be important for alniditan transdermal delivery by electroporation. …
The aim of this study was to evaluate the transdermal permeation of alniditan by electroporation and to compare with iontophoretic de …
Pharmacokinetic profile of alniditan nasal spray during and outside migraine attacks.
Roon KI, Soons PA, Uitendaal MP, de Beukelaar F, Ferrari MD. Roon KI, et al. Br J Clin Pharmacol. 1999 Mar;47(3):285-90. doi: 10.1046/j.1365-2125.1999.00894.x. Br J Clin Pharmacol. 1999. PMID: 10215753 Free PMC article. Clinical Trial.
AIMS: To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement. METHODS: Twenty-seven migraine patients (a …
AIMS: To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the rela …
The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial.
Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlöf C, Mathew N; Study Group. Diener HC, et al. Cephalalgia. 2001 Jul;21(6):672-9. doi: 10.1046/j.0333-1024.2001.00222.x. Cephalalgia. 2001. PMID: 11531899 Clinical Trial.
Alniditan 1.4 mg was significantly better (P < 0.001) than placebo and sumatriptan was significantly better (P = 0.015) than alniditan 1.4 mg. ...For alniditan, a dose-dependent adverse event relationship was seen. The safety profile of alniditan 1. …
Alniditan 1.4 mg was significantly better (P < 0.001) than placebo and sumatriptan was significantly better (P = 0.015) than al …
Treatment of migraine attacks with intranasal alniditan: an open study.
Diener HC, Louis P, Schellens R, De Beukelaar F; Study Group. Diener HC, et al. Cephalalgia. 2001 Mar;21(2):140-4. doi: 10.1046/j.1468-2982.2001.00182.x. Cephalalgia. 2001. PMID: 11422097
In this open phase-II clinical tolerability trial 17 neurologists enrolled a total of 112 patients and instructed them to administer a maximum of two doses of intranasal alniditan, a 5-HT1B/D receptor agonist, for the treatment of three consecutive migraine attacks of mode …
In this open phase-II clinical tolerability trial 17 neurologists enrolled a total of 112 patients and instructed them to administer a maxim …
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, Haegeman G, Schotte A, Van Gompel P, Wouters R, Lesage AS. Leysen JE, et al. Mol Pharmacol. 1996 Dec;50(6):1567-80. Mol Pharmacol. 1996. PMID: 8967979
Alniditan was more potent than sumatriptan at 5-HT1D-type and 5-HT1A receptors. ...In signal transduction assays using cells expressing recombinant h5-HT1D alpha, h5-HT1D beta, or h5-HT1A receptors, alniditan (like 5-HT) was a full agonist for inhibition of stimulat …
Alniditan was more potent than sumatriptan at 5-HT1D-type and 5-HT1A receptors. ...In signal transduction assays using cells expressi …
Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs.
Van de Water A, D'Aubioul J, Van Gerven W, Van Ammel K, De Clerck F. Van de Water A, et al. Eur J Pharmacol. 1996 Mar 28;299(1-3):127-37. doi: 10.1016/0014-2999(95)00848-9. Eur J Pharmacol. 1996. PMID: 8901015
The potency of alniditan was higher than that of sumatriptan and comparable to that of ergotamine (dose producing a 50% reduction: alniditan = 5.1 micrograms/kg i.v.; sumatriptan = 13.1 micrograms/kg i.v.; ergotamine = 4.6 micrograms/kg i.v.; median values). ...The …
The potency of alniditan was higher than that of sumatriptan and comparable to that of ergotamine (dose producing a 50% reduction: …
Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand.
Bonaventure P, Schotte A, Cras P, Leysen JE. Bonaventure P, et al. Recept Channels. 1997;5(3-4):225-30. Recept Channels. 1997. PMID: 9606727
[3H]alniditan, a new potent non-indole serotonin 5-HT1B/1D agonist, was used as a radioligand to characterize 5-HT1B and 5-HT1D receptor (previously termed 5-HT1D beta and 5-HT1D alpha) in various regions of the human brain. ...Very low densities were detected in various c …
[3H]alniditan, a new potent non-indole serotonin 5-HT1B/1D agonist, was used as a radioligand to characterize 5-HT1B and 5-HT1D recep …
Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Subcutaneous Alniditan Study Group.
Goldstein J, Dahlöf CG, Diener HC, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ. Goldstein J, et al. Cephalalgia. 1996 Nov;16(7):497-502. doi: 10.1046/j.1468-2982.1996.1607497.x. Cephalalgia. 1996. PMID: 8933995 Clinical Trial.
Alniditan was superior to placebo in reducing the associated symptoms of nausea, phonophobia and photophobia, and in increasing patients' functional ability. ...Both of these suggestions warrant further and larger trials of alniditan in acute migraine....
Alniditan was superior to placebo in reducing the associated symptoms of nausea, phonophobia and photophobia, and in increasing patie …
The therapeutic future in headache.
Rapoport AM. Rapoport AM. Neurol Sci. 2012 May;33 Suppl 1:S119-25. doi: 10.1007/s10072-012-1056-3. Neurol Sci. 2012. PMID: 22644186 Review.
Other future treatments that will not be discussed include transcranial magnetic stimulation, a 5-HT(1F) agonist named alniditan, large conductance calcium-activated potassium channel openers, glial modulators or other medications and devices in early stages of development …
Other future treatments that will not be discussed include transcranial magnetic stimulation, a 5-HT(1F) agonist named alniditan, lar …
The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT1B/1D receptors.
De Vries P, Willems EW, Heiligers JP, Villalón CM, Saxena PR. De Vries P, et al. Eur J Pharmacol. 1998 Jun 19;351(2):193-201. doi: 10.1016/s0014-2999(98)00301-x. Eur J Pharmacol. 1998. PMID: 9687003
The dose of alniditan that decreased arteriovenous anastomotic conductance by 50% was 24 +/- 8 microg kg(-1) (64 +/- 20 nmol kg(-1)). Alniditan produced a slight bradycardia (maximum change: -4 +/- 1%) and a more pronounced hypotensive effect (maximum change: -23 +/ …
The dose of alniditan that decreased arteriovenous anastomotic conductance by 50% was 24 +/- 8 microg kg(-1) (64 +/- 20 nmol kg(-1)). …
27 results